Romanian Pharmaceutical Producer Antibiotice Receives EIB Advisory Support for Future Growth and Expansion

ROMANIAN PHARMACEUTICAL R&D PROJECT
Romania: Pharmaceutical producer Antibiotice to benefit from EIB guidance on strengthening corporate governance and investment capacity

(IN BRIEF) The European Investment Bank will provide advisory support to Romanian pharmaceutical producer Antibiotice SA to strengthen its corporate governance framework and investment readiness. The cooperation aims to align the company’s operational and risk-management practices with international pharmaceutical industry standards while improving transparency, sustainability, and long-term competitiveness. Antibiotice, Romania’s largest pharmaceutical company with majority Romanian ownership, manufactures more than 200 products and exports medicines to over 50 countries worldwide. The EIB advisory support, provided through the InvestEU Advisory Hub, is intended to help the company attract financing, support future investments, and reinforce its role within the European pharmaceutical sector.

(PRESS RELEASE) IAȘI, Romania, 13-May-2026 — /EuropaWire/ — European Investment Bank has entered into a new advisory services agreement with Antibiotice SA aimed at strengthening the pharmaceutical producer’s corporate governance framework and enhancing its capacity to attract financing and support future strategic investments.

The cooperation will focus on aligning Antibiotice’s risk management systems and operational governance practices with international standards and best practices commonly applied across the global pharmaceutical industry. The advisory support is intended to improve transparency, operational oversight, sustainability, and long-term competitiveness as the company continues expanding in both domestic and international healthcare markets.

The initiative builds on the existing relationship between the EIB and Antibiotice and reflects broader European efforts to strengthen industrial resilience, pharmaceutical production capabilities, and healthcare supply chains across the region.

Ioannis Tsakiris, Vice-President of the European Investment Bank, stated that strengthening companies such as Antibiotice supports healthcare systems, job creation, and broader economic growth in Romania. He noted that the partnership demonstrates the EIB’s commitment to helping strategic industries modernize, attract investment, and contribute to sustainable economic development through the InvestEU framework.

Antibiotice, headquartered in Iași, is the largest pharmaceutical producer with majority Romanian ownership and manufactures more than 200 products for human and veterinary use. The company employs more than 1,300 people and exports pharmaceutical products to over 50 countries worldwide.

The company is also recognized internationally for its production of the active pharmaceutical ingredient Nystatin, maintaining a leading global position in its manufacture for more than a decade. Since 2017, the Nystatin produced by Antibiotice has been recognized by the United States Pharmacopeia as the international reference standard for quality.

Ioan Nani, Director General of Antibiotice SA, described the partnership as an important step in supporting the company’s long-term strategic development and aligning its operations with the highest international industry standards. He stated that the advisory expertise provided by the EIB will help create stronger foundations for future investments, support sustainable growth, and reinforce the company’s international expansion while maintaining its commitment to delivering high-quality medicines.

Antibiotice has continued investing in production capacity expansion, innovation, and supply chain security in recent years as part of efforts to strengthen its position within the European pharmaceutical sector. The company also stated that sustainability principles remain integrated throughout its operations through responsible resource use and environmental impact reduction initiatives.

The EIB is providing the advisory services through the InvestEU Advisory Hub, a European Union initiative that supports public and private organizations in developing sustainable investment projects and improving institutional capacity.

The partnership comes as European institutions continue encouraging the strengthening of domestic pharmaceutical manufacturing capabilities, critical medicine supply chains, and industrial competitiveness amid evolving healthcare and geopolitical challenges.

Background information  

About Antibiotice

Antibiotice SA is the largest pharmaceutical manufacturer with majority Romanian capital, with over 70 years of expertise in the development of generic medicines aligned with the international standards, which consistently contributes to improving public health both at the national level and in over 50 countries worldwide.

For over a decade, Antibiotice SA has maintained its position as the world leader in the production of the active pharmaceutical ingredient Nystatin and, since 2017, the Nystatin manufactured by the company has been recognized by the United States Pharmacopeia (USP) as the international reference standard for quality.

Antibiotice SA keeps strengthening its role as a strategic manufacturer in the European pharmaceutical industry through continual investments in developing its production capacities and in innovation, thus contributing to securing the supply chain and ensuring access to critical and essential medicines. At the same time, Antibiotice SA integrates the principles of sustainability in all its operations, through the responsible use of resources and limitation of the environmental impact, with the aim of protecting health, resources and life and of supporting long-term sustainable development.

EIB Group 

The European Investment Bank (ElB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion of new financing and advisory services for over 870 high-impact projects in eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investment union. Beyond long-term loans for large infrastructures, the EIB Group crowds-in private investment for high-risk innovative projects and businesses, with a growing role in Europe’s markets for venture debt, venture capital, guarantees and securitisations.

The European Investment Fund (EIF) is the subsidiary of the EIB Group specialised in providing guarantees and equity to improve access to finance for small and medium size businesses and startups across Europe. Acting as an anchor investor, through its extensive network of partnering banks and investment funds, the EIF mobilizes private investment and nurtures the ecosystem of venture capital funds to support innovative European entrepreneurs.

In 2023, the EIF together with six member states (France, Germany, Italy, Spain, Belgium and the Netherlands) launched the European Tech Champions Initiative, a fund of funds to scale-up innovative startups. This initiative has already enabled the creation of 12 European venture capital mega-funds and scaled up 38 companies, including 11 unicorns (with more than €1 billion in capital).

EIB Advisory

In addition to financing, the EIB Group offers advisory services that help public and private clients develop markets, build capacity and support high impact investment projects. In 2025 EIB Advisory helped accelerate project delivery and crowd in finance for 179 projects worth more than €80 billion inside and outside the European Union.

InvestEU

The InvestEU programme provides the European Union with long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps to crowd in private investment for the European Union’s strategic priorities such as the European Green Deal and the digital transition. InvestEU brings all EU financial instruments previously available for supporting investments within the European Union together under one roof, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub, and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners that will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.

Photos of the EIB Group’s spokespeople and headquarters, logo files and video B-roll for media use are available here.

Media contacts:

Clara Wanjek-Bauer
c.wanjek-bauer@ext.eib.org
+352 4379 – 79529

Press Office
press@eib.org
+352 4379 21000
www.eib.org/press

SOURCE: European Investment Bank